Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Hepatology International

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s12072-017-9798-xPMID 28550391PMCID PMC6876989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial

  2017cited by this paper
• Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.

  2017cited by this paper
• Emerging treatments for primary sclerosing cholangitis

  2017cited by this paper
• Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.

  2017cited by this paper
• Gut microbiome and liver disease.

  2017cited by this paper
• Nonalcoholic Fatty Liver Disease and the Gut Microbiome.

  2016cited by this paper
• Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats.

  2016cited by this paper
• Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

  2016cited by this paper
• Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis

  2016cited by this paper
• Intestinal microbiota in liver disease.

  2016cited by this paper
• Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

  2016cited by this paper
• The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

  2016cited by this paper
•  Report of the Baveno VI Consensus Workshop.

  2016cited by this paper
• Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD

  2016cited by this paper
• Interaction of gut microbiota with bile acid metabolism and its influence on disease states

  2016cited by this paper
• Innate Immunity and Inflammation in NAFLD/NASH

  2016cited by this paper
• Non-alcoholic fatty liver and the gut microbiota

  2016cited by this paper
• Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites

  2016cited by this paper
• Microbiota-induced obesity requires farnesoid X receptor

  2016cited by this paper
• Gut Microbiota and the Liver: A Tale of 2 Cities: A Narrative View in 2 Acts.

  2016cited by this paper
• Interaction of gut microbiota with bile acid metabolism and its influence on disease states

  2016cited by this paper
• Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling.

  2015cited by this paper
• The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics

  2015cited by this paper
• The intestinal microbiota: its role in health and disease

  2015cited by this paper
• Attenuated portal hypertension in germ‐free mice: Function of bacterial flora on the development of mesenteric lymphatic and blood vessels

  2015cited by this paper
• The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.

  2015cited by this paper
• Review article: alcohol and gut microbiota ‐ the possible role of gut microbiota modulation in the treatment of alcoholic liver disease

  2015cited by this paper
• Proton pump inhibitors alter the composition of the gut microbiota

  2015cited by this paper
• Dysbiosis‐induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice

  2015cited by this paper
• Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.

  2015cited by this paper
• The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation

  2015cited by this paper
• The Gut Microbiota and Nonalcoholic Fatty Liver Disease

  2015cited by this paper
• Gut-liver axis in alcoholic liver disease.

  2015cited by this paper
• Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

  2014cited by this paper
• Bile acids and the gut microbiome

  2014cited by this paper
• Altered profile of human gut microbiome is associated with cirrhosis and its complications.

  2014cited by this paper
• Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

  2014cited by this paper
• Host-Microbiome Interactions in Alcoholic Liver Disease

  2014cited by this paper
• Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

  2014cited by this paper
• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

  2014cited by this paper
• Interleukin-6 Modulation of Intestinal Epithelial Tight Junction Permeability Is Mediated by JNK Pathway Activation of Claudin-2 Gene

  2014cited by this paper
• Innovative and Emerging Technologies in GI Physiology and Disease Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function

  2014cited by this paper
• Immune tolerance in liver disease

  2014cited by this paper
• Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins.

  2014cited by this paper
• Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites

  2014cited by this paper
• Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

  2013cited by this paper
• Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis

  2013cited by this paper
• Linkage of gut microbiome with cognition in hepatic encephalopathy.

  2012cited by this paper
• Acetaldehyde disrupts tight junctions in Caco-2 cell monolayers by a protein phosphatase 2A-dependent mechanism.

  2012cited by this paper
• Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

  2012cited by this paper
• Microbial Translocation in Chronic Liver Diseases

  2012cited by this paper
• The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension

  2012cited by this paper
• Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut

  2012cited by this paper
• Effect of pre- and probiotics on liver regeneration after resection: a randomised, double-blind pilot study.

  2012cited by this paper
• Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

  2012cited by this paper
• A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy

  2012cited by this paper
• Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

  2011cited by this paper
• Characterization of fecal microbial communities in patients with liver cirrhosis

  2011cited by this paper
• The unfolding web of innate immune dysregulation in alcoholic liver injury.

  2011cited by this paper
• Pathogen Recognition by the Innate Immune System

  2011cited by this paper
• Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.

  2011cited by this paper
• Pattern recognition receptors and inflammation.

  2010cited by this paper
• Intestinal Goblet Cells and Mucins in Health and Disease: Recent Insights and Progress

  2010cited by this paper
• Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis

  2010influential reference
• NF-kappaB signalling: embracing complexity to achieve translation.

  2010cited by this paper
• Toll-like Receptor 4 and Hepatic Fibrogenesis

  2010cited by this paper
• Elevated endotoxin levels in non-alcoholic fatty liver disease

  2010cited by this paper
• Toll-Like Receptors in the Pathogenesis of Alcoholic Liver Disease

  2010cited by this paper
• Sterile inflammation: sensing and reacting to damage

  2010cited by this paper
• Epithelial barriers in homeostasis and disease.

  2010cited by this paper
• Management of varices and variceal hemorrhage in cirrhosis.

  2010cited by this paper
• Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis

  2010cited by this paper
• MyD88 Adapter-like (Mal)/TIRAP Interaction with TRAF6 Is Critical for TLR2- and TLR4-mediated NF-κB Proinflammatory Responses*

  2009cited by this paper
• Signalling pathways in alcohol-induced liver inflammation.

  2009cited by this paper
• Oral Propranolol Decreases Intestinal Permeability in Patients With Cirrhosis: Another Protective Mechanism Against Bleeding?

  2009cited by this paper
• The inflammasomes: guardians of the body.

  2009influential reference
• β‐Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta‐analysis

  2009cited by this paper
• Oxidative Stress and Alcoholic Liver Disease

  2009cited by this paper
• The Opposite Effects of Acute and Chronic Alcohol on Lipopolysaccharide-Induced Inflammation Are Linked to IRAK-M in Human Monocytes1

  2009cited by this paper
• The liver as a lymphoid organ.

  2009cited by this paper
• Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease.

  2008cited by this paper
• Toll‐like receptors and adaptor molecules in liver disease: Update

  2008cited by this paper
• Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.

  2007cited by this paper
• The inflammasome in pathogen recognition and inflammation

  2007influential reference
• Pattern recognition receptors: A contemporary view on liver diseases

  2006influential reference
• Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor.

  2006cited by this paper
• Pathogen recognition and innate immunity.

  2006cited by this paper
• The expanding role of the bile acid receptor FXR in the small intestine.

  2006cited by this paper
• Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling.

  2005cited by this paper
• Bacterial translocation (BT) in cirrhosis

  2005cited by this paper
• Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases

  2005cited by this paper
• Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis

  2004cited by this paper
• NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.

  2004cited by this paper
• Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats

  2003cited by this paper
• Small Intestinal Motility Disturbances and Bacterial Overgrowth in Patients With Liver Cirrhosis and Portal Hypertension

  2003cited by this paper
• Effect of Lactobacillus-Fermented Diets on Bacterial Translocation and Intestinal Flora in Experimental Prehepatic Portal Hypertension

  2003cited by this paper
• Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats

  2003cited by this paper
• Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia

  2002cited by this paper
• The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.

  2002cited by this paper
• Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites

  2000cited by this paper

• Research advances on gut microbiota dysbiosis and chronic liver diseases: a review

  2026cites this paper
• Comparison of inflammatory markers and microflora in cirrhotic patients with portal vein thrombosis: a retrospective study

  2026cites this paper
• Research Advances and Therapeutic Potential of Gut Microbiota in Metabolic Diseases

  2026cites this paper
• Targeting gut–liver–kidney axis: microbiota-derived metabolites and therapeutic implications

  2026cites this paper
• Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis

  2025cites this paper
• Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease

  2025cites this paper
• Machine learning algorithms reveal gut microbiota signatures associated with chronic hepatitis B-related hepatic fibrosis

  2025cites this paper
• Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review

  2025influential citation
• Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in ACLF

  2025cites this paper
• Probiotics for the Management of Liver Cirrhosis and Its Complications.

  2025cites this paper
• A Systematic Review of Microbiota in Cirrhosis: A Change Towards a More Pathogenic Predisposition

  2025cites this paper
• Uridine diphosphate-glucose 6-dehydrogenase-mediated glucuronidation and its emerging role in gut-liver immune regulation

  2025cites this paper
• Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation

  2025cites this paper
• Non-Alcoholic Fatty Liver Disease in Poultry: Risk Factors, Mechanism of Development, and Emerging Strategies

  2025cites this paper
• Gut microbiota dysbiosis exacerbates polystyrene microplastics-induced liver inflammation via activating LPS/TLR4 signaling pathway in ducks

  2025cites this paper
• METTL3-Driven m6A Modification of Cpt1a Gene in High Fat Diet Related Liver Cancer Tumor Macrophages Facilitates Type II Macrophage Differentiation.

  2025cites this paper
• Impact of fasting and refeeding on immune markers, hepatic gene expression, and gut microbiota in geese: insights into metabolic regulation and gut-liver interactions

  2025cites this paper
• Hepatic encephalopathy treatment after transjugular intrahepatic portosystemic shunt: a new perspective on the gut microbiota

  2025cites this paper
• The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma

  2025cites this paper
• Effect of cirrhosis on prognosis in patients with acute-on-chronic liver failure: a systematic review and meta-analysis

  2025cites this paper
• Sinensetin Ameliorates Lipopolysaccharide-Induced Liver Injury by Targeting the TLR4/NF-κB/NLRP3 Pathway and Related Gut-Liver Axis Dysfunction in Mice.

  2025cites this paper
• Induction of hepatic immuno-oxidative stress in broilers by co-exposure to lipopolysaccharide and diquat: An integrated phenotypic and transcriptomic investigation

  2025cites this paper
• Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights

  2025cites this paper
• Serum Villin-1-A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation.

  2025cites this paper
• Heat-Inactivated Lactiplantibacillus plantarum FRT4 Alleviates Diet-Induced Obesity via Gut–Liver Axis Reprogramming

  2025cites this paper
• Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma

  2025cites this paper
• Gut Barrier, Microbial Metabolites, and Immune Homeostasis in Autoimmune Hepatitis: From Molecular Mechanisms to Strategies.

  2025cites this paper
• Recent advances in the role of polysaccharides in liver diseases: a review

  2025cites this paper
• Circulating microbiome profiling in transjugular intrahepatic portosystemic shunt patients: 16S rRNA vs. shotgun sequencing

  2025cites this paper
• Investigating the common genetic basis between inflammatory bowel disease and metabolic syndrome through genomic structural equation modeling

  2025cites this paper
• Gut microbiota and atrial cardiomyopathy

  2025cites this paper
• Plant polyphenols as natural bioactives for alleviating lipid metabolism disorder: Mechanisms and application challenges.

  2025cites this paper
• Study on the Influence of Intestinal Flora on the Pathogenesis and Treatment Strategy of Related Complications of Liver Cirrhosis

  2025cites this paper
• Causal relationship between metabolic dysfunction-associated fatty liver disease and endotoxin biomarkers: A Mendelian randomization study

  2025cites this paper
• Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease

  2024cites this paper
• Zinc glycinate alleviates LPS-induced inflammation and intestinal barrier disruption in chicken embryos by regulating zinc homeostasis and TLR4/NF-κB pathway.

  2024cites this paper
• Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug.

  2024cites this paper
• Liver cirrhosis and complications from the perspective of dysbiosis

  2024cites this paper
• Minimal Hepatic Encephalopathy.

  2024cites this paper
• Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)

  2024cites this paper
• Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis

  2024cites this paper
• The Potential Mechanism of the Anti-Liver Fibrotic Effect of Curcumin in the Gut-Liver Axis

  2024cites this paper
• Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

  2024cites this paper
• Liver damage and immune responses

  2024cites this paper
• The Application of Rifaximin in Patients with End Stage Liver Disease

  2024cites this paper
• Analysis of Mannose‐Binding Lectin Protein and mRNA Levels on Selected Chicken Breeds in South Africa

  2024cites this paper
• Existence and distribution of the microbiome in tumour tissues of children with hepatoblastoma

  2024cites this paper
• Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective

  2024cites this paper
• Endothelial Dysfunction and Liver Cirrhosis: Unraveling of a Complex Relationship

  2024cites this paper
• Blood Microbiota and Its Products: Mechanisms of Interference with Host Cells and Clinical Outcomes

  2024cites this paper
• Effect of Probiotics on Portal Hypertension (PH) with Cirrhosis: A Systematic Review and Meta-Analysis.

  2024cites this paper
• Cu exposure induces liver inflammation via regulating gut microbiota/LPS/liver TLR4 signaling axis.

  2024cites this paper
• Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases

  2024cites this paper
• Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis

  2024cites this paper
• Viral Liver Disease and Intestinal Gut–Liver Axis

  2024cites this paper
• Therapeutic Potential of ZnO-Nanoparticles Synthesized Using Portulaca oleracea in Cancer Treatment: A Comprehensive Narrative Review

  2024cites this paper
• From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?)

  2024cites this paper
• Recent Approaches in Portal Hypertension Involving Risk Stratification and Medical Management.

  2023cites this paper
• Gut microbiome and atrial fibrillation—results from a large population-based study

  2023cites this paper
• ПОРТАЛДЫҚ ГИПЕРТЕНЗИЯ (ӘДЕБИ ШОЛУ)

  2023cites this paper
• The role of curcumin in the liver-gut system diseases: from mechanisms to clinical therapeutic perspective

  2023cites this paper
• The role of the gut microbiome and its metabolites in cerebrovascular diseases

  2023cites this paper
• Pyroptotic MAITs link microbial translocation with severity of alcohol-associated liver disease

  2023cites this paper
• The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases

  2023cites this paper
• State of the art in research on the gut-liver and gut-brain axis in poultry

  2023cites this paper
• Microbiota: its contribution to carcinogenesis and immunity in the lungs

  2023cites this paper
• Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis

  2023cites this paper
• Protective Effects and Mechanism of Polysaccharides from Edible Medicinal Plants in Alcoholic Liver Injury: A Review

  2023cites this paper
• Probiotics Bifidobacterium lactis M8 and Lactobacillus rhamnosus M9 prevent high blood pressure via modulating the gut microbiota composition and host metabolic products

  2023cites this paper
• Predictive Effects of Platelet Indices in Cirrhotic Patients with or without Portal Vein Thrombosis

  2023cites this paper
• Editorial: Interplay between gut microbiota and the immune system in liver surgery and liver diseases

  2023cites this paper
• Impact of Transjugular Intrahepatic Shunt Creation on the Gut Microbiota.

  2023cites this paper
• Disrupted intestinal mucosal barrier mediated by alcohol consumption aggravates systemic microplastic accumulation.

  2023cites this paper
• The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

  2023cites this paper
• New challenges in cholangiocarcinoma candidates for elective surgery: harnessing the microbiome dysbiosis

  2023cites this paper
• Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC

  2023cites this paper
• Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota

  2023cites this paper
• Portal vein computed tomography imaging characteristics and their relationship with bleeding risk in patients with liver cirrhosis undergoing interventional therapy

  2023cites this paper
• Toll-like receptor 5 tunes hepatic and pancreatic stellate cells activation

  2023cites this paper
• Alterations in hepatic transcriptome and cecum microbiota underlying potential ways to prevent early fatty liver in laying hens.

  2023cites this paper
• Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota

  2023cites this paper
• Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?

  2023cites this paper
• Titanium dioxide nanoparticles: revealing the mechanisms underlying hepatotoxicity and effects in the gut microbiota

  2023cites this paper
• Antibiotic-Induced Dysbiosis of the Gut Microbiota Impairs Gene Expression in Gut-Liver Axis of Mice

  2023cites this paper
• Portal Hypertension in Alcohol-Associated Hepatitis

  2023cites this paper
• Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?

  2023cites this paper
• Retrospective Investigation of Factors Affecting Mortality in Spontaneous Bacterial Peritonitis

  2023cites this paper
• Food, gut barrier dysfunction, and related diseases: A new target for future individualized disease prevention and management

  2023cites this paper
• Increased Microbial Translocation is a Prognostic Biomarker of Different Immune Responses to ART in People Living with HIV

  2023cites this paper
• Is it possible to intervene early cirrhosis by targeting toll-like receptors to rebalance the intestinal microbiome?

  2022cites this paper
• Clinical features and management issues of NAFLD-related HCC: what we know so far

  2022cites this paper
• Potential Gut Microbiota Features for Non-Invasive Detection of Schistosomiasis

  2022cites this paper
• A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis

  2022cites this paper
• The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products

  2022cites this paper
• Intestinal microbiota-derived membrane vesicles and their role in chronic kidney disease.

  2022cites this paper
• Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis

  2022cites this paper
• Transjugular intrahepatic Porto-systemic shunt positively influences the composition and metabolic functions of the gut microbiota in cirrhotic patients.

  2022cites this paper
• Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives

  2022cites this paper
• Fecal Microbiota Transplantation in Decompensated Cirrhosis: A Systematic Review on Safety and Efficacy

  2022cites this paper
• Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives

  2022cites this paper